ArticleAnnals of nuclear medicine2022
Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Diagnostic accuracy of PSMA-targeted radioguided surgery in prostate cancer at multiple anatomical levels: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2026Pooled it
- Surgical radioguidance with beta-emitting radionuclides; challenges and possibilities: A position paper by the EANM.European journal of nuclear medicine and molecular imaging · 2024Guideline
- Pelvic lymph node dissection during robot-assisted radical prostatectomy: a bibliometric analysis of surgical extent, nodal staging, and lymphatic morbidity.Journal of robotic surgery · 2026Review
- Cystoscopic ICG-Guided Sentinel Lymph Node Dissection in Robotic Radical Prostatectomy: A Prospective Study.The Prostate · 2026Article
- Single Photon Emission Computed Tomography Tracer.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- Examining the association between real-world extended vs. standard pelvic lymph node dissection and early and late oncologic outcomes in men undergoing radical prostatectomy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2025Article
- Radical Prostatectomy Combined with Prostate Specific Membrane Antigen-radioguided Lymph Node Dissection is Associated with Longer Treatment-free Survival for Patients with Primary Lymph Node-positive Prostate Cancer.European urology open science · 2025Article
- Latest Advancements and Future Directions in Prostate Cancer Surgery: Reducing Invasiveness and Expanding Indications.Cancers · 2025Review
- Review
- First-in-human validation of a DROP-IN β-probe for robotic radioguided surgery: defining optimal signal-to-background discrimination algorithm.European journal of nuclear medicine and molecular imaging · 2024Article
- Review
- State of the Art in Prostate-specific Membrane Antigen-targeted Surgery-A Systematic Review.European urology open science · 2023Review
- Current status of PSMA-targeted imaging and therapy.Frontiers in oncology · 2023Review
- Whole Slide Images in Artificial Intelligence Applications in Digital Pathology: Challenges and Pitfalls.Turk patoloji dergisi · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe feasibility of tracer production of
methodsFifteen primary PCa patients with intermediate- or high-risk score according to D'Amico risk stratification who had PSMA receptor affinity with Ga-68 PSMA-11 PET/CT were enrolled. After
resultsPhysiological radiotracer distribution was similar for both imaging modalities. PCa lesions were much more visible on PET/CT. Metastatic LNs could not be visualized with SPECT/CT. Eighteen of 297 totally dissected LNs were metastatic, which were exactly the same with per-operative probe counts with sensitivity, specificity, accuracy, and negative and positive predictive value of all 100%. The median follow-up was 23.5 ± 4.6 months. tPSA reduction was > 98%. The 2.5 years biochemical recurrence-free survival, PCa-specific treatment-free survival and overall survival rates were 86,7%, 66,7% and 100%, respectively.
conclusionTc-99 m-PSMA-RG-RALRP is a promising technique for extended pelvic lymph node dissection (ePLND) during robotic surgery, which may shorten the operation time and reduce complication risks. If LN metastases is detected during surgery with PSMA-targeted probe, it may be an early indicator of PCa-spesific treatment planning. Tc-99 m-PSMA-I&S SPECT/CT is not as successful as Ga-68 PSMA-11 PET/CT for diagnosis of primary PCA lesions or LN metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.